MedCityNews reports on the importance of factoring in genetics in clinical trials. In fact, the authors argue that the risks associated with ignoring genetic factors far exceed the complications of including them and that there certainly will be a greater number of clinical trials including a genetic precision medicine component in the quest for more targeted therapies. The authors’ report that presently nearly have of all therapies in clinical trials are collecting biomarker and genetic data and that number is 73 percent for oncology trials. According to a Clinicaltrials.gov search 9,300 current trials include a genetic component. This number will grow. But complexity and complications must be considered. For example, with the inclusion criteria for a clinical trial includes a specific genetic variant finding and recruiting participants becomes more difficult. Genetic testing requires additional resources and expertise. All of this must be factored into the trial planning and execution.